4-amino-3-methyl-5-phenyl-4H-1,2,4-triazole | 38345-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-3-methyl-5-phenyl-4H-1,2,4-triazole
• 英文别名: 4-amino-3-methyl-5-phenyl-1,2,4-triazole；3-methyl-5-phenyl-[1,2,4]triazol-4-ylamine；3-methyl-5-phenyl-4H-1,2,4-triazol-4-amine；3-methyl-5-phenyl-1,2,4-triazol-4-amine
• CAS: 38345-25-4
• 化学式: C₉H₁₀N₄
• 分子量: 174.205
• InChiKey: KOVHJHABUPLXST-UHFFFAOYSA-N

物化性质

• 熔点：
  194-195 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  390.7±25.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-amino-3-methyl-5-phenyl-4H-1,2,4-triazole 、 邻硝基苯甲醛 在 一水合肼 作用下， 以 正己烷 为溶剂， 反应 6.0h， 以57%的产率得到(4H-3-methyl,5-phenyl-1,2,4-triazole-4-ylamino) (2-nitrophenyl)methanol
  参考文献：
  名称：

  芳基取代4-胺-1,2,4-三唑与苯甲醛缩合反应的研究：席夫碱和稳定半胺的结构和光谱性质

  摘要：

  摘要 合成了一系列稳定的含有3,5-二取代1,2,4-三唑衍生物的半胺醛和席夫碱。所制备化合物的结构经1H NMR、13C NMR、IR、MS和元素分析确证。还讨论了三唑环取代基对半缩醛形成的空间和电子效应。对从 4-amino-3,5-dipyridyn-2-yl-1,2,4-triazole (4, 5) 获得的半缩氨酸的单晶 X 射线衍射研究揭示了通过强 O-H 连接的中心对称二聚体的形成...... .N1Tr 氢键。发现从不对称 3-甲基,5-苯基-1,2,4-三唑获得的席夫碱是一种不同的 E-conformer，通过溶液 NMR 和晶体衍射分析 (13) 确定。不对称三唑衍生物的分子几何结构：

  DOI：

  10.1016/j.molstruc.2016.02.047
• 作为产物：
  描述：

  benzaldehyde acetylhydrazone 在 一水合肼 作用下， 以 丙醇 为溶剂， 反应 24.0h， 以75%的产率得到4-amino-3-methyl-5-phenyl-4H-1,2,4-triazole
  参考文献：
  名称：

  N—H...N and C—H...π interactions in 4-amino-3-methyl-5-(p-tolyl)-4H-1,2,4-triazole and 4-amino-3-methyl-5-phenyl-4H-1,2,4-triazole

  摘要：

  The title compounds, C10H12N4, (I), and C9H10N4, (II), have been synthesized and characterized both spectroscopically and structurally. The dihedral angles between the triazole and benzene ring planes are 26.59 (9) and 42.34 (2)degrees, respectively. In (I), molecules are linked principally by N-(HN)-N-... hydrogen bonds involving the amino NH2 group and a triazole N atom, forming R-4(4)(20) and R-2(4)(10) rings which link to give a three-dimensional network of molecules. The hydrogen bonding is supported by two different C-H-...pi interactions from the tolyl ring to either a triazole ring or a tolyl ring in neighboring molecules. In (II), intermolecular hydrogen bonds and C-H-...pi interactions produce R-3(4)(15) and R-4(4)(21) rings.

  DOI：

  10.1107/s0108270106037668

文献信息

• Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
  申请人：Brown R. Truman

  公开号：US20060089316A1

  公开（公告）日：2006-04-27

  Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

  公开了使用各种已知与3-脱氧葡萄糖酮（3DG）或其前体结合的化合物的方法，以减少对肿瘤形成的易感性和/或预防或延迟由3DG及其前体诱导的肿瘤形成。还公开了降低高果糖玉米糖浆中3DG水平的方法，以使高果糖玉米糖浆不太可能诱导肿瘤形成。
• METHODS FOR TREATING VIRAL INFECTION
  申请人：ULLAH Hemayet

  公开号：US20200297699A1

  公开（公告）日：2020-09-24

  A method effective in treating a viral infection involves administering a therapeutically effective amount of at least one compound capable of inhibiting expression of at least a portion of a virus genome containing an internal ribosomal entry site, or a pharmaceutically acceptable salt thereof. The compound has an azole moiety comprising a five member heterocyclic ring containing at least one nitrogen atom, a hydrophobic moiety bonded to the heterocyclic ring of the azole, and a donor/acceptor moiety bonded to the heterocyclic ring having at least one of hydrogen bond donor and a hydrogen bond acceptor.
• METHODS FOR TREATING AGAINST VIRUSES
  申请人：HOWARD UNIVERSITY

  公开号：US20220211673A1

  公开（公告）日：2022-07-07

  A combinatorial method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site utilizing virus (IRES-utilizing virus) in a host in need of treatment involves administering the host a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R 1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo; and either separately administering another anti-viral drug and/or pro-drug to the anti-viral drug or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt.
• US5318982A
  申请人：——

  公开号：US5318982A

  公开（公告）日：1994-06-07
• US7160893B2
  申请人：——

  公开号：US7160893B2

  公开（公告）日：2007-01-09